Related Experiment Video

Updated: Jun 18, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Seliciclib in malignancies

Ibrahim T Aldoss1, Tsewang Tashi, Apar Kishor Ganti

  • 1Creighton University Medical Center, Department of Internal Medicine, Omaha, NE, USA.

Expert Opinion on Investigational Drugs
|November 27, 2009
PubMed

Insights

Seliciclib, a cyclin-dependent kinase (CDK) inhibitor, shows promise in cancer treatment by halting cell growth and inducing apoptosis. Ongoing trials are evaluating its efficacy in non-small cell lung and nasopharyngeal carcinomas.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Pharmacology

Background:

  • Cyclins and cyclin-dependent kinases (CDKs) regulate the cell cycle; their dysregulation is implicated in human diseases, particularly cancer.
  • Uncontrolled cell proliferation driven by aberrant cell cycle regulation is a hallmark of cancer.

Purpose of the Study:

  • To investigate the therapeutic potential of Seliciclib (CYC202, R-roscovitine), a second-generation CDK inhibitor, in cancer treatment.
  • To elucidate the mechanisms of action and pharmacokinetic profile of Seliciclib.

Main Methods:

  • Seliciclib was evaluated as a CDK inhibitor targeting ATP binding sites.
  • Mechanisms including p53 activation, RNA processing inhibition, and transcription blockage were assessed.
  • Pharmacokinetic properties, including oral bioavailability and metabolism, were studied.
  • Adverse effects were documented in clinical trials.

Main Results:

  • Seliciclib inhibits cyclin E/CDK2, cyclin H/CDK7, and cyclin T/CDK9, leading to cell cycle arrest and apoptosis.
  • The drug activates the p53 gene, inhibits RNA processing and RNA polymerase II-dependent transcription, and reduces anti-apoptotic proteins.
  • Seliciclib exhibits good oral bioavailability, rapid distribution, and renal excretion of its carboxylated metabolite.
  • Common adverse effects include electrolyte disturbances, gastrointestinal issues, fatigue, hyperglycemia, and elevated liver enzymes and creatinine.

Conclusions:

  • Seliciclib demonstrates significant anti-cancer activity through multiple molecular pathways.
  • Its pharmacokinetic profile supports oral administration, though food intake affects absorption.
  • Adverse effects are manageable and reversible, warranting further investigation.
  • Seliciclib is currently in Phase II trials for non-small cell lung cancer and nasopharyngeal carcinoma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...